POSITIVELY PRECISE.

We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More

Pipeline

Esperion is a pharmaceutical company focused on developing and commercializing non-statin, once-daily, oral, LDL-C–lowering therapies for the treatment of patients with hypercholesterolemia.

learn more

RECENT PRESS RELEASES

Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Esperion to Participate in Upcoming Investor Conferences
view all

HEARTS & MINDS BLOG

view all